Andere Sprachen Reviva Pharmaceuticals Holdings, Inc.

Aktien

A2QK7Q

US76152G1004

RVPH

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 10.05.2024			% 5 Tage	% 1. Jan.
1.87 ^USD	-12.62%		-41.19%	-63.69%

15.04.	Reviva Pharmaceuticals Holdings, Inc. erhält Übereinstimmung mit der U.S. Food and Drug Administration (FDA) für sein Phase-3-Zulassungsprogramm für Brilaroxazin bei Schizophrenie	CI
15.04.	Reviva Pharmaceuticals Holdings, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting	09.05.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	07.05.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH	28.04.
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH	25.04.
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia	15.04.
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	15.04.
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15.04.
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights	15.04.
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting	26.03.
Reviva to Present at the UBS Virtual CNS Day	11.03.
Reviva to Present at the 36th Annual ROTH Conference	07.03.
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	20.02.
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	06.02.
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference	25.01.
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones	04.01.
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum	11.12.
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference	30.11.
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering	20.11.
Reviva Pharmaceuticals Holdings, Inc. announced that it has received $2.999942 million in funding	20.11.
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	16.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Reviva Pharmaceuticals Holdings, Inc.

Aktien

A2QK7Q

US76152G1004

RVPH

Andere Sprachen

Filter